Genkyotex Plans 'Solo' Pivotal Trials After Lead Product Hits Phase II PBC Targets
Executive Summary
The CEO Genkyotex says its lead molecule therapy's mechanism of action has been validated by good short-term effects on patients with the autoimmune liver disease primary biliary cholangitis in a Phase II trial.
You may also be interested in...
Keeping Track: Rebuff Of Iclaprim Creates Early Pileup Of CRLs For Novel Drugs
The latest drug development news and highlights from our US FDA Performance Tracker.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.